{"entity":{"id":"trampoline-pharma","kind":"company","name":"TrAMPoline Pharma","aka":["Trampoline Pharma, Inc.","TRAMPOLINE PHARMA, INC."],"tldr":"TrAMPoline Pharma is developing MightyTIL, tumour-infiltrating immune cells taken from a patient's tumour and genetically strengthened before being returned, for sarcoma, head and neck cancer and melanoma. It is in laboratory testing.","summary":"TrAMPoline Pharma develops autologous cellular immunotherapies for solid tumours. Its lead candidate MightyTIL is a gene-engineered tumour-infiltrating lymphocyte product using its coR8:Amp technology, which the company says enhances T cell receptor binding to cancer cells and T cell receptor signalling; it targets sarcoma, head and neck cancer and melanoma, and showed greater anti-tumour activity than unmodified TIL in animal models, according to the company. In fiscal year 2026 NCI awarded it USD 398,039 under SBIR award 1R43CA310292-01 for a universal T cell receptor therapy tested first against acute myeloid leukaemia.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.trampolinepharma.com/"},{"label":"NIH RePORTER: SBIR award 1R43CA310292-01","url":"https://reporter.nih.gov/project-details/11315490"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy","tcr-t"],"targets":[],"drugs":["mightytil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on trampolinepharma.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Aurora, CO","country":"US","companyType":"cell-therapy","website":"https://www.trampolinepharma.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":398039,"source":"https://reporter.nih.gov/project-details/11315490","note":"NCI SBIR award (R43) 1R43CA310292-01: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization"}]},"route":"/companies/trampoline-pharma/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"mightytil","kind":"drug","name":"MightyTIL","route":"/drugs/mightytil/"}]}}